Biote Corp. filings document the public-company disclosures of a Nasdaq-listed hormone optimization and healthy aging business. Recent Form 8-K reports furnish quarterly and annual operating results, including procedure revenue, dietary supplement revenue, margins, adjusted EBITDA measures and commercial-priorities commentary for the Biote-certified provider network.
The company’s SEC record also includes Regulation FD investor presentation filings, definitive proxy materials for annual meeting matters, and securities information for its Class A common stock. Other material-event filings address operational and financial effects of a voluntary recall involving specific hormone pellet lots shipped by Asteria Health, Biote’s wholly owned 503B manufacturer of compounded bioidentical hormones.
Biote Corp. reported 2025 revenue of $192.2 million, down 2.5% from 2024, as procedure revenue declined 8.8% while dietary supplements grew 19.1%. Gross margin improved to 71.5%, and operating income rose 12.5% to $35.6 million helped by lower operating expenses from a sales reorganization.
Net income jumped to $31.6 million (diluted EPS $0.74) from $0.05 million (EPS $0.09), largely influenced by a $13.0 million gain from changes in earnout liabilities. Adjusted EBITDA declined 8.1% to $53.5 million, with margin slipping to 27.8%. For 2026, Biote guides revenue to above $190 million and Adjusted EBITDA above $38 million, reflecting a planned step-up in sales and technology investments, with procedure revenue expected to fall in the first half before returning to growth in the second half.
biote Corp. reported that its wholly owned subsidiary, F.H. Investments, Inc. (Asteria Health), has initiated a voluntary recall of certain hormone pellet lots shipped between May 20, 2025 and January 19, 2026 because of a potential presence of metal particulate matter. The recall is being carried out with the knowledge of the U.S. Food and Drug Administration.
The company expects to record a one-time charge of approximately $1.3 million to fourth quarter cost of products for the write-off of affected pellet inventory and currently estimates additional recall-related costs of about $1.0 million in 2026. biote does not believe its fourth quarter business was affected beyond the inventory write-off and does not anticipate a material impact on its ability to supply pellets to practitioner partners or on practitioners’ ability to serve patients.
biote Corp. (BTMD) reported Q3 2025 results showing lower sales but continued profitability. Total revenue was $47.96M, down from $51.38M a year ago, as product revenue softened. Income from operations was $8.27M versus $12.18M last year. Net income attributable to stockholders was $8.19M, or diluted EPS of $0.22, compared with $0.33 a year ago.
For the first nine months of 2025, revenue totaled $145.81M and net income attributable to stockholders was $25.09M. Operating cash flow for the period was $27.63M, illustrating solid cash generation. Cash and equivalents were $28.05M, with a term loan balance of $104.69M and $50.0M available under the revolving credit facility.
The company reduced obligations tied to prior settlements: share repurchase liabilities were $40.46M (current and long-term combined) at quarter end, aided by a September amendment to repurchase 2.8M Class V shares for $12.5M, which was paid on October 6, 2025. The fair value of earnout liabilities declined to $5.36M from $17.24M, contributing to other income.
biote Corp. (BTMD) reported that it issued a press release covering financial results for the third quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 to an Item 2.02 Form 8-K.
The company notes the information is being furnished, not filed, which means it is not subject to Section 18 liability and is not incorporated by reference unless specifically stated.
biote Corp. (BTMD) reported a return to profitability for the quarter ended June 30, 2025 while carrying meaningful leverage and ongoing contingent liabilities. Total revenue for the quarter was $48.9 million (product revenue $47.7M), roughly flat year-over-year, and operating income improved to $10.8 million from $6.2M a year earlier. Net income for the quarter was $3.9 million and net income attributable to Biote stockholders was $3.2 million (basic EPS $0.10), reversing prior-year losses. For the six months, net income was $19.8 million and revenue totaled $97.9 million.
On the balance sheet, cash declined to $19.6 million from $39.3M at year-end and total assets fell to $104.8 million. Total liabilities remained elevated at $183.6 million, leaving a stockholders' deficit attributable to Biote of $85.1 million. The company remains in compliance with its credit covenants on a Term Loan that matures in May 2027. Significant items in the period include a $8.9 million mark-to-market gain on earnout liabilities and settlement activity that reduced share repurchase liabilities following a $25.1M repurchase payment.